NCT06805864View on ClinicalTrials.gov

Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2030

Conditions
Cervical AdenocarcinomaCervical Adenosquamous Carcinoma
Interventions
DRUG

Pembrolizumab (KEYTRUDA®)

Pembrolizumab is administered at 200 mg every 3 weeks for the first 2 cycles during Chemo-CIRT, after completion of radiotherapy, the dose is increased to 400 mg and given every 6 weeks for a total of 17 cycles over 2 years.

Trial Locations (1)

371-8511

Gunma University Hospital, Maebashi

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Gunma University

OTHER